Biotest AG (BIO) | WebDisclosure

Switch to English

8302	Sociétés
115129	Mots-clés
55450	Articles
62533	Communiqués

Accueil
Sociétés
Biotest AG

COMMUNIQUÉ DE PRESSE

publié le 28/03/2024 à 12:38, il y a 7 mois 24 jours

Biotest AG increased sales by 32% in the financial year 2023
Biotest AG reported 32% increase in sales for FY 2023, reaching revenue of €684.6 million. EBIT forecast achieved at €143 million. Key developments include Yimmugo marketing authorization in the US and successful Phase III study with fibrinogen

Sales Increase EBIT Forecast Biotest AG Yimmugo Fibrinogen
COMMUNIQUÉ DE PRESSE

publié le 29/02/2024 à 07:45, il y a 8 mois 21 jours

Biotest achieves EBIT forecast for 2023
Biotest achieves EBIT forecast for 2023, with EBIT of €143 million, meeting expectations. Sales reached €684 million, encompassing one-off effects. Final figures to be released on 28 March 2024

Financial Results Annual Report EBIT Forecast Biotest AG Preference Dividend
BRÈVE

publiée le 29/02/2024 à 07:45, il y a 8 mois 21 jours

Biotest announces performance in line with forecasts for 2023

Financial Results Biotest AG Turnover EBIT 2023 Preferential Dividend
BRÈVE

publiée le 29/02/2024 à 07:45, il y a 8 mois 21 jours

Biotest annonce une performance conforme aux prévisions pour 2023

Chiffre D'affaires Résultats Financiers Biotest AG EBIT 2023 Dividende Préférentiel
COMMUNIQUÉ DE PRESSE

publié le 28/02/2024 à 10:00, il y a 8 mois 22 jours

Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care
Prof Dr Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne, emphasizing vital contribution to patient care. Plasma donation in Germany crucial for medical supply

Germany Patient Care Biotest AG Karl Lauterbach Plasma Donation
BRÈVE

publiée le 28/02/2024 à 10:00, il y a 8 mois 22 jours

Visit of Karl Lauterbach to the plasma donation center of Biotest AG in Cologne

Germany Biotest AG Karl Lauterbach Plasma Donation Medical Care
BRÈVE

publiée le 28/02/2024 à 10:00, il y a 8 mois 22 jours

Visite de Karl Lauterbach au centre de donation de plasma de Biotest AG à Cologne

Allemagne Biotest AG Don De Plasma Karl Lauterbach Soins Médicaux
COMMUNIQUÉ DE PRESSE

publié le 14/02/2024 à 08:30, il y a 9 mois 7 jours

Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate. Study results confirm safety profile & effectiveness equal to standard care in reducing blood loss. Biotest aims to address global medical need with USD 800 million market potential

Biotest AG Fibrinogen Concentrate Phase III Trial Study Results Medical Market Potential
COMMUNIQUÉ DE PRESSE

publié le 28/11/2023 à 09:00, il y a 11 mois 23 jours

EQS-News: Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation
COMMUNIQUÉ DE PRESSE

publié le 02/11/2023 à 08:00, il y a 1 année

Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023

Les Echos

Publié le 21/11/2024 à 06:58, il y a 21 heures 17 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 21 heures 17 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 21 heures 17 minutes

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 1 jour 8 heures

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 1 jour 8 heures

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 22/11/2024 à 00:00, il y a 4 heures 15 minutes

Gratomic Announces Company and Operational Update
Publié le 21/11/2024 à 22:05, il y a 6 heures 10 minutes

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Publié le 21/11/2024 à 21:50, il y a 6 heures 25 minutes

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Publié le 21/11/2024 à 20:15, il y a 8 heures

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Publié le 21/11/2024 à 20:10, il y a 8 heures 5 minutes

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform

Voir tout ACCESSWIRE

EQS Group

Publié le 21/11/2024 à 19:01, il y a 9 heures 14 minutes

Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 21/11/2024 à 18:36, il y a 9 heures 39 minutes

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Publié le 21/11/2024 à 17:58, il y a 10 heures 17 minutes

Funding Circle Plc: POS-Transaction in Own Shares
Publié le 21/11/2024 à 17:51, il y a 10 heures 23 minutes

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Publié le 21/11/2024 à 17:51, il y a 10 heures 23 minutes

LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.